Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUniversidad Politecnica de Madrid

About this trial

The aim of this study is to analyze a population with symptoms associated with adverse reactions to foodstuffs (ARFS). To determine the levels of food-specific immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) antibody reactions (AbR).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults (>18 years of age)

To present symptoms related to adverse reactions to foodstuffs (ARFS)

Disqualifiers

Antibiotic treatment

Trial population

Adults presenting symptoms related to adverse reactions to foodstuffs and/ or with suspicion of having a food allergy or food intolerance

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

  • Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions

    Diagnostic test

    Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Food-specific Immunoglobulin G4 antibody reactions

Immunoassay kits (NutriSMART® In-Vitro Diagnostic kit, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.

Time frame
0 days

Secondary outcomes

1

Food-specific Immunoglobulin E antibody reactions

Immunoassay kits (Fastcheckpoc20® In-Vitro Diagnostic kit, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.

Time frame
0 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.